|
Pharmaceutical Products – Supply Of Everolimus (Doe), Riluzole (Doe), Alpha 1 Antitrypsin (Doe), Arsenic Trioxide (Doe), Plasma-Derived C1 Inhibitor (Doe) And Human Prothrombin Complex In Their Different Compositions. 1 - L1_Everolimus (Doe) With Indication For Advanced Breast Cancer With Positive Hormone Receptor, For Neuroendocrine Tumors Of Pancreatic Origin,2 - L2_Riluzol (Doe) Orodispersible Film,3 - L3_Riluzol (Doe) Tablet,4 - L4_Riluzol (Doe) Oral Suspension,5 - L5_Alfa1 Antitrypsin (Doe) With A Concentration Of 50 Mg/Ml After Reconstitution,6 - L6_Alfa1 Antitrypsin (Doe) With A Concentration Of 25 Mg/Ml After Reconstitution,7 - L7_Arsenic Trioxide (Doe) 1Mg/Ml,8 - L8_Arsenic Trioxide (Doe) 2Mg/Ml,9 - L9_Plsma-Derived C1 Inhibitor (Doe) Container 2 Vials Of 500 Iu For Preoperative Treatment And Prevention Of Angioedema Crisis In Adults,10 - L10_Plasma-Derived C1 Inhibitor (Doe) Containers Of 1 Vial 500 Iu, 1,500 Iu And 2,000 Iu For Preoperative Treatment And Prevention Of A,11 - L11_Human Prothrombin Complex With Coagulation Factors Ii (400960 Iu), Vii (200500 Iu), Ix (400620 Iu), X (4401,200 Iu), Protein C (300,12 - L12_Human Prothrombin Complex With Coagulation Factors Ii (280760 Iu), Vii (180480 Iu), Ix (500 Iu), X (360600 Iu), Protein C (260620 U,13 - L13_Human Prothrombin Complex With Coagulation Factors Ii (450850 Iu), Vii (500 Iu), Ix (600 Iu), X (600 Iu), And Protein C At Least 400
|
